Pharmacotherapeutic monitoring of oncological patients in palliative care during hospitalization

Authors

DOI:

https://doi.org/10.30968/rbfhss.2024.153.1151

Abstract

of cancer patients admitted to an exclusive palliative care unit at a reference institute in Rio de Janeiro. Method: An observational, descriptive, retrospective study with a quantitative approach was conducted. The population consisted of patients admitted and under pharmaceutical care monitoring from June 2022 to May 2023. Data were collected from physical medical records, institutional electronic systems, and specific spreadsheets. Sociodemographic, clinical, and pharmacotherapeutic variables were analyzed. Results: A total of 283 patients were evaluated, ranging in age from 21 to 85 years, with the majority being 60 years or older (n=153; 54.1%; mean age = 60.1; standard deviation = 8.2) and predominantly female (n=186; 65.7%). The most frequent primary tumor site was the digestive system (n=56; 19.8%) followed by breast and gynecological sites (n=55; 19.4%). Regarding comorbidities, most patients had at least one (n=166; 58.7%), with the circulatory system (n=121; 42.7%) being predominant. The percentage of patients with DRP was 50.9% (n=144). A total of 298 DRP were observed, among which the non-use of the necessary medication for the patient was highlighted (n=106; 35.6%). A total of 302 interventions were performed, mainly regarding the inclusion of a new medication (n=87; 28.8%). There was a 93% acceptance rate of the interventions performed. Conclusion: The clinical role of the pharmacist within a multidisciplinary team enables the identification of Drug-Related Problems (DRPs), thereby contributing to the rational and safe use of medications through the optimization of prescriptions and rationalization of pharmacotherapy.

Downloads

Download data is not yet available.

References

World Health Organization. WHO definition of palliative care [Internet]. Geneva: WHO; 2019.

Ministério da Saúde. Ministério normatiza cuidados Paliativos no SUS [Internet]. Brasília: Ministério da Saúde; 2018. [cited in 2023 Apr 02].

World Hospice Palliative Care Alliance. Global atlas of palliative care at the end of life [Internet]. Geneva: WHO; 2020.

Freire MEM, Sawada NO, França ISX et al. Qualidade de vida relacionada à saúde de pacientes com câncer avançado: uma revisão integrativa. Rev Esc Enferm USP. 2014;48(2):357-367.

Maltoni M, Nanni O, Pirovano M et al. Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care. J Pain Symptom Manage. 1999;17(4):240-247. doi: 10.1016/s0885-3924(98)00146-8.

Cordeiro LAF, Silva TH, Oliveira LC et al. Systemic inflammation and nutritional status in patients on palliative cancer care: a systematic review of observational studies. Am J Hosp Palliat Med. 2020;37(7):565-571. doi: 10.1177/1049909119886833.

Cruz NAO, Nobrega MR, Gaudencio MRB et al. The role of the multidisciplinary team in palliative care in the elderly. Res Soc Dev. 2021;10(8). doi: 10.33448/rsd-v10i8.17433.

Brasil. Conselho Federal de Farmácia. Resolução CFF n° 585, de 29 de agosto de 2013. Regulamenta as atribuições clínicas do farmacêutico e dá outras providências. Diário Oficial [da] República Federativa do Brasil. 2013 Sep 25; Seção 1: p. 186.

Conselho Federal de Farmácia. Serviços farmacêuticos diretamente destinados ao paciente, à família e à comunidade: contextualização e arcabouço conceitual. Brasília; 2016. 200p.

Santana SPD, Gonçalves KAM. Reações adversas a medicamentos: um problema de saúde pública. Braz J Health Rev. 2021;4(6):28899-28915. doi:10.34119/bjhrv4n6-427.

Melgaço TB, Carrera JS, Nascimento DEB, et al. Polifarmácia e ocorrências de possíveis interações medicamentosas. Rev Para Med. 2011;25(1):jan-mar.

Instituto Nacional de Câncer (Brasil). Hospital do Câncer IV. Rio de Janeiro: INCA; 2022 [cited 2023 Apr 04].

Instituto Nacional de Câncer (Brasil). TNM: classificação de tumores malignos. 6ª ed. Rio de Janeiro: INCA; 2004.

Wells RHC, et al. CID-10: classificação estatística internacional de doenças e problemas relacionados à saúde. São Paulo: EDUSP; 2011.

Karnofsky DA, Burchenal JH. Experimental observations on the effects of the nitrogen mustards on neoplastic tissues. Cancer Res. 1947 Jan;7(1):50. PMID: 20278229.

Comité de consenso. Segundo consenso de Granada sobre problemas relacionados con medicamentos. Ars Pharm. 2002;43(3-4):175-184.

Otero-Lopez MJ; et.al. Actualización de la clasificación de errores de medicación del grupo ruiz-jarabo 2000 [updated classification for medication errors by the ruiz-jarabo 2000 group]. Farm Hosp. Spanish. 2008 Jan-Feb;32(1):38-52.

Bastos BR, Pereira AKS, Castro CC, et al. Perfil sociodemográfico dos pacientes em cuidados paliativos em um hospital de referência em oncologia do estado do Pará, Brasil. Rev Pan-Amaz Saude. 2018;9(2):31-36. doi: 10.5123/S2176-62232018000200004.

Francisco PM, Friestino JKO, Ferraz RO, et al. Prevalência de diagnóstico e tipos de câncer em idosos: dados da pesquisa nacional de saúde 2013. Rev Bras Geriatr Gerontol. 2020;23(2):e200023. doi: 10.1590/1981-22562020023.200023.

Chaves JHB, Neto LMA, Tavares VMC, et al. Cuidados paliativos: conhecimento de pacientes oncológicos e seus cuidadores. Rev Bioét. 2021 Jul-Sep;29(3).

Douberin CA, Silva LSR, Matos DP, et al. Principais comorbidades associadas à neoplasia mamária em tratamento quimioterápico. Rev Enf UFPE Online. 2019 Maio;13(5):1295-9.

Muniz AHR, Rosa KSC, Resende JMD, et al. Factors associated with karnofsky performance status and its trajectory in the last month of life in patients with terminal cancer. Rev Bras Cancerol. 2023;69(1):e-092754. doi: 10.32635/2176-9745.RBC.2023v69n1.2754.

Yates P, Charalambous A, Fennimore L, et al. Position statement on cancer nursing’s potential to reduce the growing burden of cancer across the world. Support Care Cancer. 2021;29:3435–3437. doi: 10.1007/s00520-021-06030-1.

Fernandes MCP, Mattos LFV, Barbosa MF. Conciliação medicamentosa em cuidados paliativos oncológicos. Rev Bras Cancerol. 2021 Set 30;67(4). doi: 10.32635/2176-9745.RBC.2021v67n4.1360.

Lima TAM, Furini AAC, Atique TSC, et al. Análise de potenciais interações medicamentosas e reações adversas a anti-inflamatórios não esteroides em idosos. Rev Bras Geriatr Gerontol. 2016;19(3):533-544. doi: 10.1590/1809-98232016019.150062.

Ko M, Kim S, Suh S, et al. Consultation-based deprescribing service to optimize palliative care for terminal cancer patients. J Clin Med. 2023;12:7431. doi: 10.3390/ jcm12237431.

Souza IG, Nascimento MG, Ramalho-de-Oliveira D, et al. Description of a comprehensive medication management service in an adult intensive care unit. Rev Bras Farm Hosp Serv Saude. 2020;11(2):0400. doi: 10.30968/rbfhss.2020.112.0400.

Crul M, Oosterhof P. The oncology pharmacist as part of the palliative treatment team. Int J Pharm Pract. 2020;28:92-96. doi: 10.1111/ijpp.12583.

Viana SSC, Arantes T, Ribeiro SCC. Intervenções do farmacêutico clínico em uma Unidade de Cuidados Intermediários com foco no paciente idoso. Einstein (São Paulo). 2017;15(3):283-8. doi: 10.1590/S1679-45082017AO3894.

Krzyżaniak N, Pawłowska I, Bajorek B, et al. An overview of pharmacist roles in palliative care: a worldwide comparison. Med Paliatywna w Praktyce. 2016;10(4):160-173.

Published

2024-09-26

How to Cite

1.
LIMA VM, BRASILEIRO LA, MELO RM, OLIVEIRA LC, MATTOS LF. Pharmacotherapeutic monitoring of oncological patients in palliative care during hospitalization. Rev Bras Farm Hosp Serv Saude [Internet]. 2024Sep.26 [cited 2024Dec.11];15(3):e1151. Available from: https://www.rbfhss.org.br/sbrafh/article/view/1151

Issue

Section

ORIGINAL ARTICLES